Disease modification in OA — will we ever get there?
Lohmander, L. Stefan LU
and Roos, Ewa M.
LU
(2019)
In Nature Reviews Rheumatology
- Abstract
No drugs are currently approved that change the natural course of osteoarthritis (OA) and translate to long-term, clinically relevant benefits. Two-stage clinical trial designs for OA have now received FDA approval, but remaining challenges lie in defining suitable study populations, surrogate outcomes and pivotal long-term, clinically relevant trial endpoints.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/62ac21d7-beb8-43c0-a5be-bffd91c0ac69
- author
- Lohmander, L. Stefan
LU
and Roos, Ewa M.
LU
- organization
- publishing date
- 2019-02-07
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Nature Reviews Rheumatology
- publisher
- Nature Publishing Group
- external identifiers
-
- scopus:85061242517
- pmid:30733580
- ISSN
- 1759-4790
- DOI
- 10.1038/s41584-019-0174-1
- language
- English
- LU publication?
- yes
- id
- 62ac21d7-beb8-43c0-a5be-bffd91c0ac69
- date added to LUP
- 2019-02-20 09:32:04
- date last changed
- 2024-04-15 23:29:26
@misc{62ac21d7-beb8-43c0-a5be-bffd91c0ac69,
abstract = {{<p>No drugs are currently approved that change the natural course of osteoarthritis (OA) and translate to long-term, clinically relevant benefits. Two-stage clinical trial designs for OA have now received FDA approval, but remaining challenges lie in defining suitable study populations, surrogate outcomes and pivotal long-term, clinically relevant trial endpoints.</p>}},
author = {{Lohmander, L. Stefan and Roos, Ewa M.}},
issn = {{1759-4790}},
language = {{eng}},
month = {{02}},
publisher = {{Nature Publishing Group}},
series = {{Nature Reviews Rheumatology}},
title = {{Disease modification in OA — will we ever get there?}},
url = {{http://dx.doi.org/10.1038/s41584-019-0174-1}},
doi = {{10.1038/s41584-019-0174-1}},
year = {{2019}},
}